Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
 | AB INBEV | - | 30 | -0,16 % | |
| ARGENX | - | 10 | -0,11 % | ||
| MELEXIS | - | 4 | +0,08 % | |
| ELIA GROUP | - | 4 | +0,30 % | |
| UMICORE | - | 2 | +0,06 % | |
| AGEAS | - | 1 | -0,37 % | |
| KBC GROEP NV | - | 1 | +0,25 % | |
| GBL | - | 1 | +0,06 % | |
| MONTEA | - | 1 | +3,44 % | |
| AEDIFICA | - | 1 | -0,33 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | Should Altria sell off its Anheuser-Bush InBev stake? It's complicated | 27 | Seeking Alpha | ||
| Sa | argenx SE: argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP | 3 | GlobeNewswire (USA) | ||
| Fr | UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B | 2 | BioPharma Dive | ||
| Fr | Belgian pharma UCB to buy U.S.-based Neurona for up to $1.15B | 1 | Seeking Alpha | ||
| Fr | UCB übernimmt Neurona Therapeutics für bis zu 1,15 Milliarden US-Dollar | 1 | Investing.com Deutsch | ||
| Fr | UCB pays $650M+ for Neurona, marking 'strategic expansion' into regenerative medicine | 3 | FierceBiotech | ||
| Fr | UCB to acquire Neurona Therapeutics for up to $1.15 billion | 2 | Investing.com | ||
| Fr | UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science | 895 | PR Newswire | Acquisition builds on UCB's 30-year heritage and leadership as an innovator in epilepsy and accelerates entry into next generation disease-modifying therapies.
... ► Artikel lesen | |
| Fr | Umicore - Transparency notification by Amundi SA | 4 | GlobeNewswire (USA) | ||
| Fr | Ageas announces the Ordinary and Extraordinary General Meetings of Shareholders of ageas SA/NV | 262 | GlobeNewswire (Europe) | Ageas announces the Ordinary and Extraordinary General Meetings of Shareholders of ageas SA/NV
As the quorum required for the Extraordinary General Meeting of Shareholders of Wednesday 22 April... ► Artikel lesen | |
| Do | Ageas publishes its 2025 reports | 276 | GlobeNewswire (Europe) | Ageas publishes its 2025 reports
Ageas has today released its 2025 Annual Reporting. It covers the Report of the Board of Directors, which includes Ageas's corporate sustainability report, as well... ► Artikel lesen | |
| Do | KBC Asset Management enters Europe's ETF market with world equity ETF: BSWC | 3 | ETF Express | ||
| Mi | Umicore - Transparency notifications by BlackRock, Inc. | 17 | GlobeNewswire (USA) | ||
| Mi | GOLDMAN SACHS stuft Argenx auf 'Buy' | 371 | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Argenx von 807 auf 827 Euro angehoben und die Einstufung auf "Buy" belassen. Die Niederländer seien einer der größten... ► Artikel lesen | |
| Mi | Insolvenzverwalter schließt Verkauf der Magnetec-Gruppe an Aperam erfolgreich ab | 4 | Recht & Politik | ||
| Mi | ANHEUSER-BUSCH INBEV SA/NV - AB InBev reports on the progress of its share buy-back program announced on 30 October 2025 | 6 | SENS | ||
| Di | Solvay S.A.: Participation notifications by Citigroup Inc. | 317 | GlobeNewswire (Europe) | Press release Regulated information
Brussels, April 14, 2026, 18:00 CEST
In line with Belgian transparency legislation (Law of... ► Artikel lesen | |
| Di | Argenx: TD Cowen bekräftigt Kaufempfehlung wegen starker Vyvgart-Performance | 3 | Investing.com Deutsch | ||
| Di | Argenx shares see TD Cowen reiterate Buy on Vyvgart strength | 5 | Investing.com | ||
| Di | Melexis: Lüftertreiber-IC | 4 | channel-e |
1 2 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.